A 1890-g newborn on total parenteral nutrition (TPN) had phenylalanine levels reaching 4164 mM indicating phenylketonuria (PKU). Review of 64 PKU cases from the California Newborn Screening Program disclosed another newborn diagnosed while on TPN. Phenylalanine levels rose five times faster with TPN, as estimated from rates in these infants. Thus, TPN use is associated with very high phenylalanine levels in newborns with PKU. When starting TPN soon after birth (for example, on day 1), early detection of PKUFby newborn screening 12 to 24 h after infusions are begunFshould be helpful in limiting exposures to toxic levels of phenylalanine.
Introduction
In the 1980s, an amino-acid formulation for intravenous use was designed to reproduce the amino-acid profile of a breast-fed infant. 1 Such solutions are now widely used for nutrition in preterm babies. However, the possibility of increased levels of circulating amino acids has been a concern with use of parenteral nutrition in infants. 2 Perhaps, the uncertainty is greatest when parenteral nutrition is used before newborn screening for inborn errors of metabolism. Here, we report extremely high phenylalanine levels in a parenterally fed newborn with phenylketonuria (PKU).
Case presentation A 1890-g female was born following a 34-week pregnancy and a spontaneous vaginal delivery to a 26-year-old, gravida 2 para 1 mother. Membranes had ruptured before delivery, and the mother presented to the hospital with contractions. Apgar scores were 9 and 9 at 1 and 5 min, and the infant was active and alert. Tachypnea and grunting occurred over the first 2 h, and the child was admitted to the neonatal intensive care unit. The temperature was 36.8 1C, the pulse was 164, the blood pressure was 55/25 and the respiratory rate was 60. The length was 41.5 cm and the head circumference was 30.5 cm. The chest X-ray showed 'mild granular opacification over the lung fields,' suggesting respiratory distress syndrome. Nasal continuous positive airway pressure was used for 4 days, and breathing difficulties were resolved. Antibiotics were given for the first 7 days, until the possibility of sepsis was excluded.
Total parenteral nutrition (TPN) was begun at B28 to 29 h of life, starting at 2 g of amino acids per kilogram of body weight and increased over the next 3 to 4 days to 3 g/kg (TrophAmine; B. Braun Medical., Bethlehem, PA, USA). Phenylalanine intake was as high as 168 mg/kg of body weight per day on day 7, which included 144 mg of intravenous phenylalanine per kilogram per day ( Figure 1a) .
A heelstick blood specimen for newborn screening obtained at 66 h (day 3) showed a phenylalanine level of 1420 mM, compatible with PKU (reported on day 6; reference, <140; phenylalanine to tyrosine ratio, 57; reference, <2.3; Figures 1b and c) . Phenylalanine intake was sharply reduced on day 7, as amino-acid infusions were reduced and replaced with breast milk. A follow-up specimen at 146 h (day 7; reported late on day 8) showed a phenylalanine level of 4164 mM (phenylalanine to tyrosine ratio, 148). Amino-acid infusions were then stopped, and phenylalanine was completely excluded from the diet on days 12 to 16, through use of formula devoid of phenylalanine (Phenex-1; Abbott Nutrition; Columbus, OH, USA). (There was a weekend delay in obtaining the formula, because the hospital was not part of a metabolic center.) A diet containing 50 mg of phenylalanine per kilogram per day was started on day 17. Dihydropteridine reductase activity and urine biopterin were normal. The phenylalanine level was 304 mM at discharge on day 20.
The median phenylalanine level over the first year was 287 mM (range, 16 to 1334 mM; average, 340 mM; based on 26 measurements after discharge). Daily phenylalanine intakes were B50 mg/kg throughout the first year. Phenylalanine hydroxylase mutations were not determined, because the information was not needed for management. By 13 months, the weight was 8.5 kg (5 to 10th percentile), the length was 75 cm (25 to 50th percentile) and the head circumference was 45.5 cm (25 to 50th percentile). The child could walk alone and speak roughly 20 words, showing normal development for age. 
California PKU cases
We obtained data from the California Newborn Screening Program, covering 7 July 2005 to 24 June 2010 (2 695 430 newborn screens; Table 1 ). The study was exempt from institutional review, because we used existing data without identifiers. There were 64 infants with PKU and 58 with variant hyperphenylalaninemia. Three infants were on TPN during the period when blood was collected for newborn screening and follow-upFtwo with PKU (including our case) and one with hyperphenylalaninemia. For PKU, follow-up phenylalanine levels with TPN were higher than with oral feeding (tested at roughly the same number of hours after birth; Figure 1d ). More dramatically, the median rate of change of the phenylalanine level for the two TPN cases was 31 mM/h (individual values were 28 and 34), compared with 6.5 mM/h for oral feeding (range, À0.46 to 14.2; 51 cases; P ¼ 0.018, Mann-Whitney; Figure 1e ).
One infant with hyperphenylalaninemia received TPN (birth weight, 3835 g; phenylalanine levels, 307 and 480 mM at 17 and 140 h, respectively) and phenylalanine rose 1.4 mM/h (Figure 1d ). This was comparable to rates for orally fed infants with hyperphenylalaninemia (median, 0.24; range, À1.9 to 1.4; 51 cases; Figure 1e ). The infants had birth weights of 1890 g (current case; phenylalanine levels were 1420 mM at 66 h and 4164 mM at 146 h) and 1710 g (phenylalanine levels were 596 mM at 34 h and 2150 mM at 89 h). d The infant had a birth weight of 3835 g, and phenylalanine levels were 307 and 480 mM at 17 and 140 h, respectively. e Two infants only, both on TPN. Further details are in footnote c and the text. f Birth weight, 1980 g. g For these 11 infants, there was no follow-up level reported (9 infants), or the follow-up level reported was obtained after treatment was started (2 infants). h For these 6 infants, there was no follow-up level reported (4 infants), or there was a follow-up level but no collection date reported (1 infant) or the follow-up level reported was obtained after treatment started (1 infant).
Discussion

TPN in newborns
Historically, amino-acid solutions for intravenous use in infants have been in the making since the 1930s. 3 Shohl et al. 4 gave intravenous amino acids from casein hydrolysis to five infants. Helfrick and Abelson 5 infused a mixture of glucose, amino acids and an emulsion of fat in a 5-month-old boy with marasmus and Hirschsprung's disease. Wilmore and Dudrick 6 infused fibrin hydrolysate solutions through the superior vena cava in a 3-week-old girl with intestinal atresia whose nutritional condition desperately worsened in the days following surgery. Other advances were use of pure, crystalline L-amino acids 7 and a formulation that reproduced plasma amino-acid levels in normal, breast-fed infants. 1, [8] [9] [10] [11] Use of amino-acid solutions in preterm infants was envisioned in the 1970s, 2 but a trend toward early parenteral amino acids in preterm babies began later, perhaps by 1990. 12 The practice of providing infants weighing p1000 g with 2.5 to 3.5 g of intravenous amino acids per kilogram per day as soon as possible after birth is supported by nitrogen balance and growth data. [13] [14] [15] [16] [17] TPN is now commonly used in preterm newborns, starting within the first 24 h of life.
TPN in infants with PKU
The frequency of PKU in North America may be as high as one in 10 000 births 18 (roughly 400 cases per year, based on 4 million births). If neonates weighing up to 1000 g account for only 0.12% of births ((754 births per 22 months)/(345 000 total births per 12 months) in Canada 19 ), then there could be one such baby with PKU born every 2 years in the United States. Numbers will be higher for babies weighing up to 2000 gFfor example, 0.74 cases per million births in California (two newborns with PKU requiring TPN per 2 695 430 screens) or roughly 3 cases per year in the United States.
Conclusions
This is the first report of PKU diagnosed in newborns while on TPN. Their phenylalanine levels rose B30 mM/h, or five times faster than in orally fed infants with PKU. Adverse effects of high phenylalanine levels in utero are recognizedFas in maternal PKU, 20 but there are limited data on consequences of extremely high phenylalanine levels in preterm infants. Therefore, as a precaution, neonatologists may wish to consider collecting the initial newborn screening sample 12 to 24 h after starting infusions, whenever TPN is used in the early newborn period (for example, <24 h). This practice should shorten exposures to high phenylalanine levels in the rare event of PKU. A compounding pharmacy (for example, Coram Specialty Infusion Services; Mendota Heights, MN, USA) should prepare amino-acid solutions with reduced phenylalanine content as soon as PKU is diagnosed, if parenteral feeding is needed.
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